Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide in recurrent/progressive pediatric brain tumors
NCT03257631Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2017
- Primary completion
- Sep 2023
- Modality
- Molecular Glues
- Countries
- 5
01
Overview
A Phase 2 trial of pomalidomide in glioma, medulloblastoma, ependymoma, diffuse intrinsic pontine glioma (DIPG), sponsored by Celgene Corporation. Started Sep 2017; status: completed.
02
Drugs
pomalidomide
03
Conditions
gliomamedulloblastomaependymomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT03257631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257631.